Silo Pharma and Hoth Therapeutics formed a joint venture, leveraging Hoth's successful antisense therapy targeting KIT for GIST.
5 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 3
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Silo Pharma and Hoth Therapeutics formed a joint venture, leveraging Hoth's successful antisense therapy targeting KIT for GIST.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Jasper Therapeutics develops briquilimab, a new drug candidate targeting KIT, in collaboration with Karlsruhe Institute of Technology.Sub-event
Hoth Therapeutics and Silo Pharma announce a joint venture regarding Hoth's successful antisense therapy against GIST.1 source
HT-KIT, a precision antisense candidate from Hoth Therapeutics, passed GLP validation.1 source
Keep exploring
The entities involved
-
Karlsruhe Institute of Technology
technical university and research center in Karlsruhe, Germany
-
Global Information Systems Technologies Pvt. Ltd.
subscription agent in India
Nothing else this week.
Coverage
Newest first; wire copies grouped- BenzingaEXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical
- PR NewswireHoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards NEW YORK, Sept. 2
- Unknown outlet
- Unknown outlet
- Unknown outlet